(Q50893694)

English

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.

scientific article published on 20 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

2

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

10

object named as

D C Linch

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

11

object named as

R E Gale

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

author name string

C Allen

1

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

K Lamb

3

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

C Evans

4

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

S Tinsley

5

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

R Sellar

6

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

M O'Brien

7

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

J L Yin

8

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

A K Burnett

9

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

publication date

20 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

27

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

9

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

1891-1901

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

https://scigraph.springernature.com/pub.10.1038/leu.2013.186

0 references

Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Clinical implications of FLT3 mutations in pediatric AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Blood consult: acute myeloid leukemia and the t(8;21)(q22;22).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Implications of NRAS mutations in AML: a study of 2502 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Flt3-dependent transformation by inactivating c-Cbl mutations in AML

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

21 January 2018

Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

NCCN Clinical Practice Guidelines Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.186

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2013.186

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23783394

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50893694&oldid=1545562458"